Immunohistochemical evaluation of p53, Ki67, ERG, MYC and PTEN in Gleason pattern 3 prostate cancer: Implication in active surveillance.

Authors

null

Arie Carneiro

Department of Urology, ABC Medical School, Santo Andre, Brazil

Arie Carneiro , Paulo Priante Kayano , Adam G. Sowalsky , Tercia Jovino Neves Santos , Paolo Dell'oglio , Natasha Kouvaleski Saviano Moran , Lucila Heloisa Simardi Santiago , Gustavo Caserta Lemos , Marcos Tobias Machado , Rafael Sanchez-Salas , Andrew Wagner , Bianca Bianco

Organizations

Department of Urology, ABC Medical School, Santo Andre, Brazil, Department of Urology - Hospital Israelita Albert Einstein, Sao Paulo, Brazil, National Cancer Institute, Bethesda, MD, Department of Pathology - Hospital AC Camargo ( AC Camargo Cancer Center), São Paulo, Brazil, Department of Urology - Vita-Salute San Raffaele University, Milan, Italy, Department of Urology - Faculdade de Medicina do ABC, Santo Andre, Brazil, Department of Pathology - Faculdade de Medicina do ABC, Santo André, Brazil, Department of Urology - L'Institut Mutualiste Montsouris, Paris, France, Beth Israel Deaconess Medical Center, Boston, MA, Department of Genetics - Faculdade de Medicina do ABC, Santo André, Brazil

Research Funding

Other

Background: The presence of prostate cancer (PCa) Gleason pattern 4 or 5 on biopsy is a major contraindication for active surveillance (AS). Limitations of anatomopathological morphological analysis, can severely compromise the accuracy of PCa risk stratification. In this study, expression of recurrent oncogenes (MYC and ERG), tumor suppressors (PTEN and p53) and a marker of proliferation (Ki67) were evaluated as biomarkers in order to predict whether histologically indolent Gleason pattern 3 co-occurs with unsampled higher grade disease warranting further biopsy, which may in turn inform more intensive treatment. Methods: This cross-sectional study involved 37 patients diagnosed with localized PCa and very low risk who underwent radical prostatectomy. The patients were divided into two groups according to the final pathology: Group 1, Gleason score 6 (ISUP 1, n = 17) and Group 2, Gleason score 7 (ISUP 2 or 3, n = 20). The expression of proteins p53, Ki67, ERG, MYC and PTEN in FFPE samples of neoplastic and adjacent benign prostatic tissue were evaluated by digital image immunohistochemistry. Results: The expression of ERG, Ki67, and MYC was significantly higher in neoplastic tissue when compared to benign in both groups, while expression of PTEN was significantly lower. Strong p53 staining, which is enriched for gain-of-function missense alleles, did not present a significant statistical difference. When the Gleason 3 and Gleason 4 areas of group 2 were compared, no difference was observed in the expression of any of the markers studied. In the univariate analysis, comparing the absolute expression of the biomarkers in Gleason 3 PCa samples from both groups, Ki67 was the only independent predictor of adjacent Gleason 4 (ISUP 2 or 3). In the multivariate analysis, including the relative expression of the biomarkers in the Gleason 3 PCa of the two groups, age and PSA; it was observed that only PTEN (OR = 1, CI = 1.03-1.31) presented as an independent factor of adjacent Gleason 4 (ISUP 2 or 3). Conclusions: An increase in absolute Ki67 expression and loss PTEN protein expression, associated with age and PSA, were predictors of adjacent Gleason pattern 4.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Epidemiology/Outcomes

Citation

J Clin Oncol 36, 2018 (suppl; abstr e17068)

DOI

10.1200/JCO.2018.36.15_suppl.e17068

Abstract #

e17068

Abstract Disclosures

Similar Abstracts

First Author: Ekamjit Singh Deol

Abstract

2023 ASCO Genitourinary Cancers Symposium

Evaluating p53 nuclear expression and prostate cancer progression in a predominantly African American cohort.

First Author: William Gesztes

Abstract

2023 ASCO Genitourinary Cancers Symposium

RIPK2 as a prognostic biomarker and predictor of aggressive prostate cancer.

First Author: Mustafa Hammudi